Eupraxia reaches 120-patient enrollment target in Phase 2b trial of EP-104GI for eosinophilic esophagitis
Bitget2026/10/15 12:03- Eupraxia Pharmaceuticals reached its 120-patient enrollment target for the Phase 2b RESOLVE trial of EP-104GI for eosinophilic esophagitis on October 12, 2026.
- Interim results are expected in December 2026, covering symptoms, tissue findings and safety.
- Safety observations to date indicate EP-104GI has been generally well tolerated, with no treatment-related serious adverse events across both trial phases.
- Periodic data reviews indicate no enrollment increase is needed to meet the study’s statistical objectives.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
